JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type I… Read more
JCR Pharmaceuticals Co., Ltd. (JCR) - Total Liabilities
Latest total liabilities as of September 2025: €60.54 Billion EUR
Based on the latest financial reports, JCR Pharmaceuticals Co., Ltd. (JCR) has total liabilities worth €60.54 Billion EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
JCR Pharmaceuticals Co., Ltd. - Total Liabilities Trend (2022–2025)
This chart illustrates how JCR Pharmaceuticals Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
JCR Pharmaceuticals Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of JCR Pharmaceuticals Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanjing Chervon Auto Precision Technology Co Ltd
SHG:603982
|
China | CN¥4.81 Billion |
|
Ningbo Gaofa Automotive Ctrl
SHG:603788
|
China | CN¥566.99 Million |
|
Hunan Hansen Pharmaceutical Co Ltd
SHE:002412
|
China | CN¥301.66 Million |
|
Andes Technology Corp
TW:6533
|
Taiwan | NT$1.78 Billion |
|
Bairong Inc.
PINK:BAIGF
|
USA | $859.08 Million |
|
Investar Holding Corp
NASDAQ:ISTR
|
USA | $2.51 Billion |
|
EZTEC Empreendimentos e Participações S.A
SA:EZTC3
|
Brazil | R$1.79 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down JCR Pharmaceuticals Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how JCR Pharmaceuticals Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for JCR Pharmaceuticals Co., Ltd. (2022–2025)
The table below shows the annual total liabilities of JCR Pharmaceuticals Co., Ltd. from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €57.42 Billion | +25.51% |
| 2024-03-31 | €45.75 Billion | +7.59% |
| 2023-03-31 | €42.52 Billion | -7.65% |
| 2022-03-31 | €46.05 Billion | -- |